Related Experiment Video

Updated: May 29, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

[Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer]

C Gennigens1, G Jerusalem

  • 1Service d'Oncologie Médicale, CHU de Liège, Belgique. christinegennigens@yahoo.com

Revue Medicale De Liege
|September 28, 2011
PubMed

Insights

Trabectedin demonstrates efficacy in treating advanced soft tissue sarcomas and ovarian cancer, particularly after standard chemotherapy failure. Its mechanism involves interfering with DNA repair, offering a new therapeutic option for these challenging malignancies.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Chemistry

Background:

  • Soft tissue sarcomas represent 1% of all malignant tumors.
  • Doxorubicin and ifosfamide were historically the primary chemotherapies for metastatic disease.
  • Limited treatment options existed for patients with advanced or recurrent cancers.

Purpose of the Study:

  • To review the mechanism of action of trabectedin.
  • To summarize the clinical results of trabectedin in treating specific cancers.
  • To highlight trabectedin as a novel therapeutic agent.

Main Methods:

  • Review of existing literature on trabectedin's mechanism.
  • Analysis of clinical trial data regarding trabectedin's efficacy and safety.
  • Examination of its application in soft tissue sarcoma and ovarian cancer settings.

Main Results:

  • Trabectedin shows significant efficacy in patients with advanced soft tissue sarcomas.
  • It is effective in partially sensitive recurrent ovarian cancer.
  • Its mechanism involves interference with DNA repair pathways.

Conclusions:

  • Trabectedin offers a valuable treatment option for patients who have failed standard therapies.
  • Its validated use in ovarian cancer signifies its clinical importance.
  • Further research into its mechanism and applications is warranted.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...